Beta Bionics, Inc. (BBNX) shareholders
Close on Nov 17, 2026Market cap $800.28MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| T. Rowe Price Associates, Inc. | 8,943,061 | 16.60% | 13G (passive) | Sep 30, 2026 |
| Robin C. John Joint filing with Eventide Asset Management, LLC (13.40%), Finny Kuruvilla, M.D., Ph. D. (13.40%) | 5,945,488 | 13.40% | 13G (passive) amendment | Mar 31, 2026 |
| Eventide Asset Management, LLC Joint filing with Finny Kuruvilla, M.D., Ph. D. (11.32%), Robin C. John (11.32%) | 4,857,041 | 11.32% | 13G (passive) | Jan 31, 2025 |
| Levy Guy Joint filing with Soleus Capital Management, L.P. (8.60%), Soleus GP, LLC (8.60%) and 3 more | 4,828,619 | 8.70% | 13G (passive) amendment | Sep 30, 2026 |
| Spokes, Andrew J. M. Joint filing with Dapice Joshua J. (9.90%), Dreyfuss, Philip D. (9.90%) and 14 more | 4,379,920 | 9.90% | 13G (passive) amendment | Dec 31, 2025 |
| Wehrly, Mark C. Joint filing with Dapice Joshua J. (9.90%), Dreyfuss, Philip D. (9.90%) and 16 more | 4,313,920 | 9.90% | 13G (passive) amendment | Sep 30, 2025 |
| Saito Edric C. Joint filing with Dapice Joshua J. (9.70%), Dreyfuss, Philip D. (9.70%) and 16 more | 4,203,920 | 9.70% | 13G (passive) amendment | Jun 30, 2025 |
| Wellington Management Group LLP Joint filing with Wellington Group Holdings LLP (9.00%), Wellington Investment Advisors Holdings LLP (9.00%) and 1 more | 3,901,599 | 9.00% | 13G (passive) | Mar 31, 2025 |
| Soleus Capital Management, L.P. Joint filing with Guy Levy (8.80%), Soleus GP, LLC (8.80%) | 3,795,341 | 8.80% | 13G (passive) | Mar 31, 2025 |
| Morgan Stanley Joint filing with Morgan Stanley Capital Services LLC (7.80%) | 3,739,567 | 8.60% | 13G (passive) amendment | Sep 30, 2025 |
| Short Daniel S. Joint filing with Dapice Joshua J. (8.10%), Dreyfuss, Philip D. (8.10%) and 14 more | 3,607,920 | 8.10% | 13G (passive) amendment | Mar 31, 2026 |
| Sands Capital Alternatives, LLC Joint filing with Sands Frank M. (8.20%), Sands Capital Life Sciences Pulse Fund II. L.P. (8.20%) | 3,570,113 | 8.20% | 13G (passive) amendment | Jun 30, 2025 |
| RTW Investments, LP Joint filing with Roderick Wong, M.D. (7.60%) | 3,299,869 | 7.60% | 13G (passive) | Mar 31, 2025 |
| Frank M. Sands Joint filing with Sands Capital Life Sciences Pulse Fund II. L.P. (7.30%), Sands Capital Ventures, LLC (7.30%) | 3,154,409 | 7.30% | 13G (passive) | Apr 2, 2025 |
| Divisadero Street Capital, LLC Joint filing with Divisadero Street Capital Management, LP (6.90%), William Zolezzi (6.90%) and 2 more | 3,072,985 | 6.90% | 13G (passive) | Jul 17, 2026 |
| BlackRock, Inc. | 2,778,764 | 6.40% | 13G (passive) | Sep 30, 2025 |
| Guy Levy Joint filing with Soleus Capital Management, L.P. (5.70%), Soleus GP, LLC (5.70%) | 2,534,565 | 5.80% | 13G (passive) amendment | Dec 31, 2025 |
| Point72 Capital Advisors, Inc. Joint filing with Point72 Asset Management, L.P. (5.20%), Steven A. Cohen (5.20%) | 2,290,023 | 5.20% | 13G (passive) | Feb 18, 2026 |
| Israel A. Englander Joint filing with Millennium Group Management LLC (5.30%), Millennium Management LLC (5.30%) | 2,286,728 | 5.30% | 13G (passive) | Sep 15, 2025 |
| Perceptive Advisors LLC Joint filing with Joseph Edelman (5.10%), Perceptive Life Sciences Master Fund, Ltd. (5.10%) | 2,203,840 | 5.10% | 13G (passive) | Mar 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BBNX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Eventide Asset Management, LLC | 6,253,673 | 11.50% | $98.05M | +308,185 | 1.31% |
| Soleus Capital Management, L.P. | 4,393,714 | 8.08% | $68.85M | +39,213 | 2.37% |
| Morgan Stanley | 4,266,822 | 7.85% | $66.86M | +39,188 | 0.00% |
| Sands Capital Ventures, LLC | 3,708,043 | 6.82% | $58.11M | – | 9.47% |
| BlackRock, Inc. | 3,340,171 | 6.14% | $52.34M | +301,576 | 0.00% |
| Point72 Asset Management, L.P. | 2,254,683 | 4.15% | $35.33M | −270,357 | 0.04% |
| Vanguard Capital Management LLC | 1,782,346 | 3.28% | $27.93M | +54,369 | 0.00% |
| Vestal Point Capital, LP | 1,600,000 | 2.94% | $25.07M | −611,518 | 0.59% |
| Rtw Investments, LP | 1,500,000 | 2.76% | $23.51M | −500,000 | 0.20% |
| Deerfield Management Company, L.P. (Series C) | 1,324,000 | 2.44% | $20.75M | – | 0.22% |
| Omega Fund Management, LLC | 1,316,183 | 2.42% | $20.62M | – | 11.11% |
| Eversept Partners, LP | 1,249,441 | 2.30% | $19.58M | −165,397 | 1.02% |
| Divisadero Street Capital Management, LP | 1,113,802 | 2.05% | $17.45M | New | 0.40% |
| Geode Capital Management, LLC | 1,073,452 | 1.97% | $16.82M | +140,774 | 0.00% |
| State Street Corp | 970,192 | 1.78% | $15.20M | +24,105 | 0.00% |
| Millennium Management LLC | 956,244 | 1.76% | $14.98M | +95,378 | 0.01% |
| Balyasny Asset Management L.P. | 855,682 | 1.57% | $13.41M | +237,767 | 0.02% |
| Perceptive Advisors LLC | 832,944 | 1.53% | $13.05M | −10,000 | 0.20% |
| JPMorgan Chase & Co | 703,356 | 1.29% | $11.96M | +396,127 | 0.00% |
| Bruce & Co., Inc. | 665,700 | 1.22% | $10.43M | +115,000 | 2.82% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 134 | 48M | 88.2% | 30 / 56 | 35 / 23 | 6M | 7M |
| Q1 2026 | 130 | 49M | 90.7% | 24 / 47 | 47 / 47 | 14M | 10M |
| Q4 2025 | 158 | 47M | 86.9% | 46 / 60 | 31 / 16 | 8M | 9M |
| Q3 2025 | 129 | 49M | 89.3% | 29 / 58 | 21 / 16 | 10M | 6M |
| Q2 2025 | 116 | 45M | 82.5% | 28 / 38 | 27 / 13 | 7M | 4M |
| Q1 2025 | 102 | 42M | 76.7% | 102 / 0 | 0 / 0 | 42M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
121 funds held BBNX in Q2 2026, 31% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of BBNX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Eventide Gilead Fund | 3,983,917 | 7.33% | $62.43M | 1.81% | Jun 30, 2026 |
| Eventide Healthcare & Life Sciences Fund | 2,052,176 | 3.77% | $32.16M | 1.80% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,272,504 | 2.34% | $19.94M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,062,586 | 1.95% | $16.65M | 0.02% | Jun 30, 2026 |
| Bruce Fund | 665,700 | 1.22% | $10.43M | 2.78% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 469,615 | 0.86% | $7.36M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 445,440 | 0.82% | $5.71M | 0.02% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 378,433 | 0.70% | $5.93M | 0.04% | Jun 30, 2026 |
| JPMorgan Small Cap Value Fund | 221,450 | 0.41% | $3.47M | 0.26% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 208,920 | 0.38% | $2.53M | 0.01% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 200,344 | 0.37% | $2.43M | 0.01% | May 31, 2026 |
| iShares U.S. Medical Devices ETF | 189,897 | 0.35% | $2.98M | 0.10% | Jun 30, 2026 |
| Schwab U.S. Small-Cap ETF | 188,948 | 0.35% | $2.29M | 0.01% | May 31, 2026 |
| Eventide Exponential Technologies Fund | 173,298 | 0.32% | $2.72M | 2.57% | Jun 30, 2026 |
| JPMorgan U.S. Small Company Fund | 126,797 | 0.23% | $1.99M | 0.18% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Sean Saint | President & CEO, Director | 398,429 | 0.73% | Sep 4, 2026 |
| Stephen Feider | Chief Financial Officer | 159,378 | 0.29% | Nov 13, 2026 |
| Mark Hopman | Chief Commercial Officer | 54,143 | 0.10% | Nov 4, 2026 |
| Mike Mensinger | Chief Product Officer | 174,740 | 0.32% | Oct 29, 2026 |
| Steven Jon Russell | Chief Medical Officer | 207,699 | 0.38% | Sep 3, 2026 |
| Christy Jones | Director | 19,564 | 0.04% | Sep 23, 2026 |
| Danny L. Dearen | Director | 32,209 | 0.06% | May 26, 2026 |
| Sean Carney | Director | 32,209 | 0.06% | May 26, 2026 |
| Gerard J. Michel | Director | 33,509 | 0.06% | May 26, 2026 |
| Maria Palasis | Director | 29,397 | 0.05% | May 26, 2026 |
| Adam Lezack | Director | 27,399 | 0.05% | May 26, 2026 |
| Wellington Hadley Harbor Aggregator IV, L.P. | 10% owner | 3,901,599 | 7.18% | Feb 3, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Stephen Feider Chief Financial Officer | Nov 11, 2026 | Sale(10b5-1 plan) | −8,874 | $17.21 | $152.68K | 159,378 |
| Stephen Feider Chief Financial Officer | Nov 11, 2026 | Option exercise | +8,874 | $5.10 | $45.26K | 168,252 |
| Stephen Feider Chief Financial Officer | Nov 9, 2026 | Sale(10b5-1 plan) | −744 | $17.00 | $12.65K | 159,378 |
| Stephen Feider Chief Financial Officer | Nov 9, 2026 | Option exercise | +744 | $5.10 | $3.79K | 160,122 |
| Stephen Feider Chief Financial Officer | Nov 5, 2026 | Sale(10b5-1 plan) | −382 | $17.04 | $6.51K | 159,378 |
| Stephen Feider Chief Financial Officer | Nov 5, 2026 | Option exercise | +382 | $5.10 | $1.95K | 159,760 |
| Mark Hopman Chief Commercial Officer | Nov 2, 2026 | Sale(10b5-1 plan) | −370 | $16.90 | $6.25K | 54,143 |
| Mike Mensinger Chief Product Officer | Oct 27, 2026 | Sale(10b5-1 plan) | −2,650 | $22.00 | $58.30K | 174,740 |
| Mark Hopman Chief Commercial Officer | Oct 26, 2026 | Sale(10b5-1 plan) | −821 | $20.00 | $16.42K | 54,513 |
| Mark Hopman Chief Commercial Officer | Oct 14, 2026 | Sale(10b5-1 plan) | −775 | $17.35 | $13.45K | 55,334 |
| Mark Hopman Chief Commercial Officer | Oct 1, 2026 | Sale(10b5-1 plan) | −370 | $18.96 | $7.02K | 56,109 |
| Christy Jones Director | Sep 22, 2026 | Sale(10b5-1 plan) | −6,430 | $23.00 | $147.89K | 19,564 |
| Mark Hopman Chief Commercial Officer | Sep 16, 2026 | Sale(10b5-1 plan) | −30,779 | $20.13 | $619.58K | 56,479 |
| Mike Mensinger Chief Product Officer | Sep 16, 2026 | Sale(10b5-1 plan) | −2,650 | $22.00 | $58.30K | 177,390 |
| Mark Hopman Chief Commercial Officer | Sep 14, 2026 | Sale(10b5-1 plan) | −775 | $15.52 | $12.03K | 86,382 |
| Mark Hopman Chief Commercial Officer | Sep 9, 2026 | Sale(10b5-1 plan) | −35,994 | $18.46 | $664.45K | 88,033 |
| Mark Hopman Chief Commercial Officer | Sep 9, 2026 | Sale(10b5-1 plan) | −36,870 | $18.46 | $680.62K | 87,157 |
| Sean Saint President & CEO, Director | Sep 3, 2026 | Sale(10b5-1 plan) | −5,641 | $20.08 | $113.27K | 398,429 |
| Mark Hopman Chief Commercial Officer | Sep 2, 2026 | Sale | −5,327 | $19.11 | $101.80K | 124,027 |
| Sean Saint President & CEO, Director | Sep 2, 2026 | Sale | −16,867 | $19.11 | $322.33K | 404,070 |
| Stephen Feider Chief Financial Officer | Sep 2, 2026 | Sale | −6,675 | $19.11 | $127.56K | 159,378 |
| Mike Mensinger Chief Product Officer | Sep 2, 2026 | Sale | −4,375 | $19.11 | $83.61K | 180,040 |
| Steven Jon Russell Chief Medical Officer | Sep 2, 2026 | Sale | −4,221 | $19.11 | $80.66K | 169,628 |
| Stephen Feider Chief Financial Officer | Jun 29, 2026 | Sale(10b5-1 plan) | −4,896 | $17.03 | $83.38K | 166,053 |
| Stephen Feider Chief Financial Officer | Jun 29, 2026 | Option exercise | +4,896 | $5.10 | $24.97K | 170,949 |
| Stephen Feider Chief Financial Officer | Jun 29, 2026 | Option exercise | +4,896 | $5.10 | $24.97K | 170,827 |
| Stephen Feider Chief Financial Officer | Jun 29, 2026 | Sale(10b5-1 plan) | −4,896 | $17.03 | $83.38K | 165,931 |
| Stephen Feider Chief Financial Officer | Jun 26, 2026 | Sale(10b5-1 plan) | −5,104 | $17.05 | $87.02K | 166,053 |
| Stephen Feider Chief Financial Officer | Jun 26, 2026 | Option exercise | +5,104 | $5.10 | $26.03K | 171,157 |
| Stephen Feider Chief Financial Officer | Jun 26, 2026 | Sale(10b5-1 plan) | −5,104 | $17.05 | $87.02K | 165,931 |
| Stephen Feider Chief Financial Officer | Jun 26, 2026 | Option exercise | +4,982 | $5.10 | $25.41K | 171,035 |
| Mark Hopman Chief Commercial Officer | Jun 24, 2026 | Sale(10b5-1 plan) | −1,258 | $15.01 | $18.88K | 129,354 |
| Christy Jones Director | Jun 24, 2026 | Sale(10b5-1 plan) | −1,406 | $15.00 | $21.09K | 25,994 |
| Christy Jones Director | Jun 4, 2026 | Sale(10b5-1 plan) | −2,811 | $14.00 | $39.35K | 27,400 |
| Mark Hopman Chief Commercial Officer | Jun 4, 2026 | Sale(10b5-1 plan) | −275 | $12.31 | $3.39K | 130,612 |
| Steven Jon Russell Chief Medical Officer | Jun 2, 2026 | Sale | −4,222 | $12.61 | $53.24K | 173,849 |
| Stephen Feider Chief Financial Officer | Jun 2, 2026 | Sale | −6,676 | $12.61 | $84.18K | 166,053 |
| Sean Saint President & CEO, Director | Jun 2, 2026 | Sale | −16,872 | $12.61 | $212.76K | 420,937 |
| Mark Hopman Chief Commercial Officer | Jun 2, 2026 | Sale | −5,329 | $12.61 | $67.20K | 130,887 |
| Mike Mensinger Chief Product Officer | Jun 2, 2026 | Sale | −4,378 | $12.61 | $55.21K | 184,415 |
| Adam Lezack Director | May 22, 2026 | Sale(10b5-1 plan) | −998 | $11.21 | $11.19K | 27,399 |
| Danny L. Dearen Director | May 21, 2026 | Award | +16,965 | – | – | 32,209 |
| Christy Jones Director | May 21, 2026 | Award | +16,965 | – | – | 30,211 |
| Christy Jones Director | May 21, 2026 | Sale(10b5-1 plan) | −1,998 | $9.95 | $19.88K | 13,246 |
| Maria Palasis Director | May 21, 2026 | Award | +16,965 | – | – | 29,397 |
| Adam Lezack Director | May 21, 2026 | Award | +16,965 | – | – | 28,397 |
| Adam Lezack Director | May 21, 2026 | Sale(10b5-1 plan) | −1,000 | $9.95 | $9.95K | 11,432 |
| Sean Carney Director | May 21, 2026 | Award | +16,965 | – | – | 32,209 |
| Gerard J. Michel Director | May 21, 2026 | Award | +16,965 | – | – | 33,509 |
| Mark Hopman Chief Commercial Officer | Mar 4, 2026 | Sale(10b5-1 plan) | −353 | $11.57 | $4.08K | 139,133 |
| Mike Mensinger Chief Product Officer | Mar 2, 2026 | Sale | −1,064 | $12.36 | $13.15K | 188,793 |
| Mark Hopman Chief Commercial Officer | Mar 2, 2026 | Sale | −834 | $12.36 | $10.31K | 139,486 |
| Stephen Feider Chief Financial Officer | Mar 2, 2026 | Sale | −1,428 | $12.36 | $17.65K | 172,729 |
| Steven Jon Russell Chief Medical Officer | Mar 2, 2026 | Sale | −1,026 | $12.36 | $12.68K | 179,096 |
| Sean Saint President & CEO, Director | Mar 2, 2026 | Sale | −3,384 | $12.36 | $41.83K | 437,809 |
| Mike Mensinger Chief Product Officer | Feb 27, 2026 | Award | +109,105 | – | – | 189,857 |
| Mark Hopman Chief Commercial Officer | Feb 27, 2026 | Award | +109,105 | – | – | 140,320 |
| Stephen Feider Chief Financial Officer | Feb 27, 2026 | Award | +131,543 | – | – | 174,157 |
| Steven Jon Russell Chief Medical Officer | Feb 27, 2026 | Award | +109,105 | – | – | 180,122 |
| Sean Saint President & CEO, Director | Feb 27, 2026 | Award | +343,269 | – | – | 441,193 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Beta Bionics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 7,946 shares on Sep 18, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Stephen Feider Officer | Nov 9, 2026 | 744 | $12.65K | Nov 9, 2026 | Stock Options |
| Stephen Feider Officer | Nov 5, 2026 | 382 | $6.51K | Nov 5, 2026 | stock options |
| Mark Hopman Officer | Oct 1, 2026 | 2,660 | $50.49K | Oct 1, 2026 | Exercise of Stock Options |
| Christina Jones Director | Sep 22, 2026 | 8,942 | $197.08K | Sep 22, 2026 | Exercise of Stock Options |
| Michael Mensinger Officer | Sep 16, 2026 | 5,300 | $101.92K | Sep 16, 2026 | Series D Purchase |
| Mark Hopman Officer | Sep 16, 2026 | 28,119 | $540.73K | Sep 16, 2026 | Exercise of Stock Options |
| Mark Hopman Officer | Sep 9, 2026 | 40,305 | $779.10K | Sep 9, 2026 | Exercise of Stock Options |
| Stephen Feider Officer | Sep 3, 2026 | 6,675 | $129.60K | Sep 2, 2026 | Restricted Stock Units vesting under registered plan |
| Michael R. Mensinger Officer | Sep 3, 2026 | 4,375 | $84.94K | Sep 2, 2026 | Restricted Stock Units vesting under registered plan |
| Steven Jon Russell Officer | Sep 3, 2026 | 4,221 | $81.95K | Sep 2, 2026 | Restricted Stock Units vesting under registered plan |
| Mark Hopman Officer | Sep 3, 2026 | 5,327 | $103.42K | Sep 2, 2026 | Restricted Stock Units vesting under registered plan |
| Sean Saint Officer | Sep 3, 2026 | 5,641 | $113.26K | Sep 3, 2026 | Equity Award |
| Sean Saint Officer, Director | Sep 3, 2026 | 16,867 | $327.47K | Sep 2, 2026 | Restricted Stock Units vesting under registered plan |
| Stephen Feider Officer | Jun 29, 2026 | 4,896 | $83.38K | Jun 29, 2026 | Stock Options |
| Stephen Feider Officer | Jun 26, 2026 | 5,104 | $87.01K | Jun 26, 2026 | Stock Options |
See a number that looks wrong?